Private equity giant CVC Capital Partners is reportedly planning to sell its 60% stake in Genetic Group, an Italian pharmaceutical contract manufacturing firm, in a deal potentially valued at around €700 million, according to the Financial Times. Luxembourg-based CVC has enlisted Rothschild advisers to facilitate the sale, but declined to comment on the report when contacted by Euronews.
Founded in 2000 by Rocco Pavese, who still retains a minority stake in the company, Genetic Group specializes in the manufacturing of medical devices such as nasal sprays, inhalers, and other healthcare products. The Salerno-based company owns the intellectual property for roughly 50 products and distributes to over 30 countries worldwide. Pavese and his family are reportedly interested in keeping their minority share in the company even as CVC looks for a buyer for its own stake.
Since acquiring a majority interest in Genetic Group in 2020, CVC Capital Partners has significantly boosted the company’s earnings. Pre-tax earnings, excluding interest, depreciation, and amortization, have doubled to approximately €50 million under CVC’s ownership. This growth aligns with a broader trend in the pharmaceutical industry, as drug manufacturers increasingly outsource production to contract manufacturers like Genetic Group to cut costs and streamline operations.
The boom in contract manufacturing, especially in pharmaceuticals, has caught the attention of private equity firms. Outsourcing production allows pharmaceutical companies to avoid the significant capital investment required for in-house manufacturing, leading to efficiency gains and cost savings. For private equity players, investments in contract manufacturing companies offer a pathway into the pharmaceutical sector without the high costs and risks associated with drug research and development.
With over 1,200 employees and €193 billion in assets under management, CVC Capital Partners operates through 30 offices globally, including in countries such as Belgium, China, France, Denmark, Germany, India, and Hong Kong. It manages funds on behalf of over 300 investors, establishing itself as a leading global private equity firm with diverse interests across sectors.
CVC’s Infrastructure Expansion into Asia
In a related development, CVC’s infrastructure investment arm, CVC DIF, recently announced its acquisition of a 49.9% stake in ECO, a Singapore-based hazardous waste management company. The transaction, conducted via CVC’s DIF Infrastructure VII fund, marks CVC’s first foray into Southeast Asia. French environmental management firm Séché Environnement will retain the majority 50.1% share in ECO.
Gijs Voskuyl, managing partner at CVC DIF, expressed optimism about the investment, describing ECO’s position as a leading waste management company in Singapore with strong client relationships. “This investment marks the first of CVC DIF in Southeast Asia, on the back of CVC DIF’s global sector relationships and CVC’s widespread local office network in the region,” Voskuyl said.
Voskuyl added that the investment, along with the partnership with Séché Environnement, positions CVC to drive ECO’s growth and strengthen its leadership in sustainable infrastructure within Southeast Asia. The investment underscores CVC’s strategy to expand its infrastructure investments and leverage high-entry barriers in specialized sectors.
As CVC explores the sale of Genetic Group and expands into new international markets, the private equity firm continues to balance growth in high-potential sectors like pharmaceuticals and waste management. Both moves reflect CVC’s broader strategy to capitalize on emerging opportunities in key industries worldwide.